Drug Approval | April 18, 2022
Zydus Lifesciences receives final approval from USFDA for Cyanocobalamin Injection
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
This product is indicated for the short-term treatment of a breathing problem (apnea) in premature infants
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The drug is indicated for use in combination with other drugs
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
The large-scale production of PhytoChol in Hanau, Germany, will meet an increased market demand for cholesterol
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
The stability is led by healthy demand in the domestic and emerging markets
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Subscribe To Our Newsletter & Stay Updated
